Page: Enpr-EMA priority activities-2026/5/29

Page: Emergency Task Force (ETF) recommendations-2026/5/29

Document: EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027-2026/5/29

Page: Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline-2026/5/29

Document: List of centrally authorised products with safety-related changes to the product information-2026/5/29

Page: Expert panel support for breakthrough medical devices: pilot programme-2026/5/29

Page: Scientific advice for high-risk medical devices-2026/5/29

Document: Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking-2026/5/29

Page: Quality of medicines: questions and answers - Part 2-2026/5/29

Document: European Medicines Agency’s privacy statement for legal entity and bank account validation-2026/5/28